ESMO: Relay’s RLY-4008 Shows High Response, Lower Toxicity In Cholangiocarcinoma

 
• By Alaric DeArment
Relay Therapeutics presented data for RLY-4008 in cholangiocarcinoma at ESMO • Source: Shutterstock

More from Strategy

More from Business